Surrozen (SRZN) Cash from Operations (2020 - 2026)
Surrozen (SRZN) posted quarterly Cash from Operations of 12500000.0 for Q1 2026, down 34.71% year-over-year from 19146170.35 in Q1 2025, and down 113.89% quarter-over-quarter from 5844000.0 in Q4 2025.
Powered by 
Analysis
Surrozen (SRZN) Cash from Operations (2020 - 2026) Analysis & Trends
Surrozen's Cash from Operations history runs 7 years deep, the most recent figure standing at 12500000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 34.71% year-over-year to 12500000.0; the TTM figure through Mar 2026 stood at 33465000.0 (down 84.55% YoY), while the FY2025 annual figure was 30244000.0, down 71.84% from the prior year.
- Cash from Operations for Q1 2026 stood at 12500000.0, down from 5844000.0 in the prior quarter.
- The five-year high for Cash from Operations was 3500000.0 in Q4 2024, with the low at 18374000.0 in Q1 2022.
- The 5-year median for Cash from Operations is 8746000.0 (2024), against an average of 8520235.29.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations slumped 3550.0% in 2023, then jumped 147.95% in 2024.
- Surrozen's Cash from Operations stood at 200000.0 in 2022, then plunged by 3550.0% to 7300000.0 in 2023, then surged by 147.95% to 3500000.0 in 2024, then slumped by 266.97% to 5844000.0 in 2025, then sank by 113.89% to 12500000.0 in 2026.
- Business Quant data shows SRZN's Cash from Operations at 12500000.0 in Q1 2026, 5844000.0 in Q4 2025, and 9000000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Surrozen | 263.35 Mn | 263.35 Mn | - | -7.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.41 Mn |
| Mar 31, 2026 | -12.50 Mn |
| Dec 31, 2025 | -5.81 Mn |
| Sep 30, 2025 | -9.03 Mn |
| Jun 30, 2025 | -6.10 Mn |
| Mar 31, 2025 | -9.30 Mn |
| Dec 31, 2024 | 3.48 Mn |
| Sep 30, 2024 | -6.71 Mn |
| Jun 30, 2024 | -5.65 Mn |
| Mar 31, 2024 | -8.75 Mn |
| Dec 31, 2023 | -7.30 Mn |
| Sep 30, 2023 | -10.18 Mn |
| Jun 30, 2023 | -8.72 Mn |
| Mar 31, 2023 | -14.20 Mn |
| Dec 31, 2022 | -205,000.00 |
| Sep 30, 2022 | -14.14 Mn |
| Jun 30, 2022 | -11.40 Mn |
| Mar 31, 2022 | -18.40 Mn |
| Dec 31, 2021 | -11.54 Mn |
| Sep 30, 2021 | -14.06 Mn |